Literature DB >> 20972692

Outcome of hospitalized MDR-TB patients: Israel 2000-2005.

D Bendayan1, A Hendler, V Polansky, M Weinberger.   

Abstract

MDR-TB has emerged in Israel following an immigrations wave from the Former Soviet Union (FSU) and Ethiopia. The purpose of this study was to outline characteristics and outcome of hospitalized MDR-TB patients. We retrospectively summarized charts of MDR-TB patients hospitalized in the national referral tuberculosis centers from January 2000 to December 2005, and followed them for 2 years. One hundred thirty-two patients were identified with a median age of 40 years and male predominance (77%). The majority of the patients were immigrants from FSU (83%) and Ethiopia (7.6%). They were characterized by alcohol (25.8%) and IV drug abuse (23.5%), presented with advanced disease manifested by hypoalbuminemia (50.8%) and smear positivity (70.5%). Cure was achieved in 50.3% and 30.4% died. Factors independently associated with death were patients' age (OR = 1.036 for each year, 95%CI 1.0-1.1, p = 0.014), hypoalbuminemia (OR = 2.95, 95%CI 1.1-7.6, p = 0.025), smear positivity at diagnosis (OR = 3.7, 95%CI 1.2-11.4, p = 0.023), alcohol abuse (OR = 4.8, 95%CI 1.7-13.7, p = 0.004) and XDR-TB resistance pattern (OR 8.3, 95%CI 1.5-44.6, p = 0.014). This study brings out the poor prognosis of a highly vulnerable immigration population. Efforts should be focused on earlier diagnosis and treatment in a well controlled hospital environment and to professional support groups to attend to this population's special needs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20972692     DOI: 10.1007/s10096-010-1096-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  27 in total

1.  Drug-resistant pulmonary tuberculosis in Israel, a society of immigrants: 1985-1994.

Authors:  J Sosna; T Shulimzon; J Roznman; M Lidgi; A Lavy; I Z Ben-Dov; I Ben-Dov
Journal:  Int J Tuberc Lung Dis       Date:  1999-08       Impact factor: 2.373

2.  Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia.

Authors:  S S Shin; A D Pasechnikov; I Y Gelmanova; G G Peremitin; A K Strelis; S Mishustin; A Barnashov; Y Karpeichik; Y G Andreev; V T Golubchikova; T P Tonkel; G V Yanova; M Nikiforov; A Yedilbayev; J S Mukherjee; J J Furin; D J Barry; P E Farmer; M L Rich; S Keshavjee
Journal:  Int J Tuberc Lung Dis       Date:  2006-04       Impact factor: 2.373

3.  Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Yong Soo Kwon; Yee Hyung Kim; Gee Young Suh; Man Pyo Chung; Hojoong Kim; O Jung Kwon; Yong Soo Choi; Kwhanmien Kim; Jhingook Kim; Young Mog Shim; Won-Jung Koh
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

4.  Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?

Authors:  G B Migliori; C Lange; E Girardi; R Centis; G Besozzi; K Kliiman; L R Codecasa; A Spanevello; D M Cirillo
Journal:  Eur Respir J       Date:  2008-04       Impact factor: 16.671

5.  Characteristics of candidaemia with Candida-albicans compared with non-albicans Candida species and predictors of mortality.

Authors:  M Weinberger; L Leibovici; S Perez; Z Samra; I Ostfeld; I Levi; E Bash; D Turner; A Goldschmied-Reouven; G Regev-Yochay; S D Pitlik; N Keller
Journal:  J Hosp Infect       Date:  2005-10       Impact factor: 3.926

Review 6.  Risk factors for multidrug resistant tuberculosis in Europe: a systematic review.

Authors:  A Faustini; A J Hall; C A Perucci
Journal:  Thorax       Date:  2005-10-27       Impact factor: 9.139

7.  Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico.

Authors:  M L García-García; A Ponce de León; M E Jiménez-Corona; A Jiménez-Corona; M Palacios-Martínez; S Balandrano-Campos; L Ferreyra-Reyes; L Juárez-Sandino; J Sifuentes-Osornio; H Olivera-Díaz; J L Valdespino-Gómez; P M Small
Journal:  Arch Intern Med       Date:  2000-03-13

8.  Emergence of drug-resistant tuberculosis in Jerusalem: ten-year retrospective review.

Authors:  A M Yinnon; A Sasson; Y Schlesinger; D Raveh; Z Jerassi; B Rudensky
Journal:  Isr J Med Sci       Date:  1997-11

9.  Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina.

Authors:  D J Palmero; M Ambroggi; A Brea; M De Lucas; A Fulgenzi; D Martínez; C Mosca; R Musella; M Natiello; C Gonzalez; E Abbate
Journal:  Int J Tuberc Lung Dis       Date:  2004-06       Impact factor: 2.373

10.  Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases.

Authors:  G B Migliori; C Lange; R Centis; G Sotgiu; R Mütterlein; H Hoffmann; K Kliiman; G De Iaco; F N Lauria; M D Richardson; A Spanevello; D M Cirillo
Journal:  Eur Respir J       Date:  2008-06       Impact factor: 16.671

View more
  10 in total

1.  Map the gap: missing children with drug-resistant tuberculosis.

Authors:  C M Yuen; C A Rodriguez; S Keshavjee; M C Becerra
Journal:  Public Health Action       Date:  2015-03-21

2.  Survival of civilian and prisoner drug-sensitive, multi- and extensive drug- resistant tuberculosis cohorts prospectively followed in Russia.

Authors:  Yanina Balabanova; Vladyslav Nikolayevskyy; Olga Ignatyeva; Irina Kontsevaya; Clare M Rutterford; Anastasiya Shakhmistova; Nadezhda Malomanova; Yulia Chinkova; Svetlana Mironova; Ivan Fedorin; Francis A Drobniewski
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

Review 3.  Diabetes-related tuberculosis in the Middle East: an urgent need for regional research.

Authors:  Yosra M Alkabab; Hail M Al-Abdely; Scott K Heysell
Journal:  Int J Infect Dis       Date:  2015-09-25       Impact factor: 3.623

4.  Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009-2014.

Authors:  Benoît Henry; Matthieu Revest; Nathalie Dournon; Loïc Epelboin; Guillaume Mellon; Guillaume Bellaud; Pierre Mordant; Damien Le Dû; Nicolas Véziris; Christine Bernard; Sébastien Morel; Stéphane Jauréguiberry; Christian Michelet; Françcois Bricaire; Pierre Tattevin; Éric Caumes
Journal:  Emerg Infect Dis       Date:  2016-03       Impact factor: 6.883

5.  Association between diabetes mellitus and multi-drug-resistant tuberculosis: a protocol for a systematic review and meta-analysis.

Authors:  Balewgizie Sileshi Tegegne; Tesfa Dejenie Habtewold; Melkamu Merid Mengesha; Johannes G M Burgerhof
Journal:  Syst Rev       Date:  2017-01-14

6.  Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis.

Authors:  Joel Philip Samuels; Aashna Sood; Jonathon R Campbell; Faiz Ahmad Khan; James Cameron Johnston
Journal:  Sci Rep       Date:  2018-03-21       Impact factor: 4.379

7.  Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis.

Authors:  Balewgizie Sileshi Tegegne; Melkamu Merid Mengesha; Andreas A Teferra; Mamaru Ayenew Awoke; Tesfa Dejenie Habtewold
Journal:  Syst Rev       Date:  2018-10-15

8.  Effects of migration on tuberculosis epidemiological indicators in low and medium tuberculosis incidence countries: A systematic review.

Authors:  Sarah Jackson; Zubair Kabir; Catherine Comiskey
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-02-22

9.  Comparison of characteristics and mortality in multidrug resistant (MDR) and non-MDR tuberculosis patients in China.

Authors:  Yanni Sun; David Harley; Hassan Vally; Adrian Sleigh
Journal:  BMC Public Health       Date:  2015-10-06       Impact factor: 3.295

Review 10.  Association between Directly Observed Therapy and Treatment Outcomes in Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis.

Authors:  Jia Yin; Jinqiu Yuan; Yanhong Hu; Xiaolin Wei
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.